Abstract
While some academic researchers have been signing a pledge not to patent raw DNA sequences, companies that specialize in sequencing DNA—chiefly Incyte Pharmaceuticals of Palo Alto, California, and Human Genome Sciences of Rockville, Maryland—have been channeling data from their automated sequencers into the Patent and Trademark Office (PTO) at a torrential rate. Applications covering more than 400,000 sequences have been filed, and the PTO is seeking help in dealing with the flood
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
